Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 04 2022 - 6:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 3, 2022
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk
A/S – Share repurchase programme
Bagsværd,
Denmark, 3 May 2022 — As part of the up to DKK 24.0 billion 2022 share repurchase programme, Novo Nordisk A/S has now
initiated a new share repurchase programme for an amount of up to DKK 4.4 billion in accordance with Article 5 of Regulation No 596/2014
of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the
"Safe Harbour Rules”).
For that purpose, Novo Nordisk A/S has appointed Skandinaviska
Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken AB, as lead manager to execute the programme independently and without
influence from Novo Nordisk A/S. The purpose of the programme is to reduce the company’s share capital and to meet obligations arising
from share-based incentive programmes. Under the agreement, Skandinaviska Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken
AB, will repurchase B shares on behalf of Novo Nordisk A/S during the trading period starting 4 May 2022 and ending on 2 August 2022.
A maximum of 190,000,000 B shares in total can be bought
during the trading period. The maximum number of B shares that can be repurchased on a single trading day may not exceed 20% of the average
daily trading volume of Novo Nordisk B shares on the trading venue, on which the purchase takes place, in the preceding 20 trading days
of the purchase (excluding the day of the purchase). At least once every seven trading days, Novo Nordisk A/S will issue an announcement
in respect of the transactions made under the share repurchase programme.
Page 2 of 2
Novo Nordisk
is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes
and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80
countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs
are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
Further information
Media: |
|
|
Ambre Brown Morley |
+45 3079 9289 |
abmo@novonordisk.com |
Natalia Salomao Abrahao (US) |
+1 848 304 1027 |
niaa@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Ann Søndermølle Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
David Heiberg Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
Jacob Martin Wiborg Rode |
+45 3075 5956 |
jrde@novonordisk.com |
Mark Joseph Root (US) |
+1 848 213 3219 |
mjhr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 41 / 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: May 3, 2022 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024